KPV

KPV is the last three amino acids of alpha-melanocyte stimulating hormone, the same parent molecule behind Melanotan II and bremelanotide. The tail fragment keeps the anti-inflammatory activity and loses the pigmentation and arousal effects.

That is a tidy piece of pharmacology, and it is the reason the compound gets attention.

Why people are talking about it#

Because the mechanism is upstream. Most anti-inflammatory compounds block a single messenger. The literature on KPV describes inhibition of NF-kB signalling, one of the central switches controlling inflammatory gene expression, which is closer to turning down the master control than to blocking one channel.

The second reason is its size. Three amino acids is tiny, which makes both oral survival and skin penetration more plausible than they are for most of the peptides on this site.

What people take it for#

Gut inflammation above all, and skin problems second. It is sold to people with inflammatory bowel disease, and to people with eczema and acne as a topical.

Gut inflammation#

The claim is a calmer gut and fewer flares, resting on the NF-kB mechanism along with effects on inflammatory cytokine production.

That has been shown in mouse colitis models, where KPV reduced inflammation and tissue damage, and in cell culture.

Skin#

The claim is less redness and irritation from a cream, on the same anti-inflammatory activity. The molecule's small size makes penetration more plausible than for larger peptides, which is a mechanistic argument rather than a measured result.

What the evidence shows#

The preclinical work is genuine and reasonably consistent. Rodent colitis models, cell culture and wound healing studies all point the same direction.

Human evidence has not caught up. There is no completed trial, no dose-finding work, and no published safety study in people, so the dose, duration and interaction profile are all open questions.

How it is taken#

Sold in three formats: as a powder for reconstitution and subcutaneous injection, as capsules, and as a topical cream. The three have very different plausibility, and the cream is the one where the molecule's small size does most work.

No dose has been established in people, so the figures circulating come from community practice rather than from a trial.

How it compares#

Against the melanocortin peptides#

Melanotan II and bremelanotide come from the same parent hormone and keep the receptor activity that produces pigmentation and arousal effects. KPV is the fragment that keeps the anti-inflammatory half and drops the rest, which is why it reads as a much narrower proposition.

Against licensed anti-inflammatories#

For inflammatory bowel disease specifically, the licensed options have large randomised trials and a specialist service behind them. That is the comparison worth making, and it is not close on evidence.

Common questions#

Does it help Crohn's or colitis?

No human trial has tested that. The animal colitis data is real and is not the same thing, and both conditions have licensed treatments with proper evidence behind them.

Is it related to Melanotan?

Yes. It is a fragment of the same parent hormone, with the pigmentation activity absent.

Does the cream work?

There is no controlled human evidence either way. Its small size makes skin penetration more plausible than for larger peptides.

Why is it sold as capsules when most peptides are injected?

Three amino acids is small enough that surviving digestion is a real possibility rather than a marketing claim, which is not true of most peptides sold in capsule form.